Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.1 (
alkaline phosphatase
)
47,916
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
AmBisome
is a commercially available preparation of amphotericin B incorporated in small unilamellar liposomes. The analysis of safety data provided in a multicentre compassionate phase II/III study evaluating 133 episodes of therapy with
AmBisome
in patients with severe underlying disease is very encouraging. Rapid (30-60 min) administration of a high daily dose of
AmBisome
is feasible without the well known side effects observed with the conventional formulation of amphotericin B (Fungizone). Although eleven of 71 patients with initially normal serum creatinine concentrations showed increased values after
AmBisome
therapy, 17 patients among 50 with initially high creatinine concentrations recovered normal renal function during
AmBisome
treatment. Hypokalaemia was observed in 24 episodes of treatment (18%). Increases in serum glutamyl oxaloacetic transaminase and
alkaline phosphatase
were also quite common in this selected population with severe underlying disease and the contribution of
AmBisome
to these changes is difficult to establish.
AmBisome
appears a safe alternative to conventional amphotericin B, and its efficacy should be further investigated.
...
PMID:Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. 177 95
The liver is affected in up 50 to 75% of compromised hosts with disseminated Candida albicans infection who come to autopsy. The antemortem diagnosis of hepatic candidiasis is rarely made. Blood cultures are negative in approximately 50% of cases, and biochemical parameters of hepatic injury may be of nonspecific value. Additionally, the more commonly seen renal, cardiac, and respiratory involvement may overshadow the hepatic lesion. In a review of 17 autopsy series of disseminated candidiasis, 92 cases with hepatic involvement were identified for a mean prevalence of 13.7%. Hepatic granulomas and microabscesses were the two most common histological lesions attributable to Candida. Inflammatory aggregates, centrilobular congestion, bile stasis, and fatty change were seen less frequently. The diagnosis should be suspected in any compromised host with unexplained fever with or without elevated
alkaline phosphatase
or bilirubin levels. The diagnosis can be made by percutaneous needle biopsy or at laparoscopy in a majority of cases. Early treatment with
Amphotericin
is associated with prolonged survival.
...
PMID:The spectrum of hepatic candidiasis. 709 48
The safety of
AmBisome
was evaluated in 187 transplant recipients treated for 197 episodes. Patients included 89 bone marrow transplant recipients, 64 liver transplant recipients, 20 renal transplant recipients and 14 recipients of combined organs.
AmBisome
was instituted for verified invasive fungal infection in 34 cases, suspected invasive fungal infections in 80 cases and as prophylaxis in 83 cases.
AmBisome
was given for a median of 11 days (range 1-112 days) with a maximum daily dose of 1.49 +/- 0.70 mg/kg/day (mean +/- SD). The total cumulative dose of
AmBisome
was 1.11 +/- 1.78 g (mean +/- SD). Side-effects definitely attributed to
AmBisome
therapy included low potassium (n = 3), low back pain (n = 3), dyspnoea (n = 2), allergic rash (n = 1), nausea and vomiting (n = 1), confusion (n = 1), rise in
alkaline phosphatase
(n = 1) and cholecystitis (n = 1) with an overall incidence of 13 of 197 (7%).
AmBisome
was discontinued due to side-effects in 6 (3%) of the cases. During
AmBisome
treatment the mean cyclosporin dose was 9.6 +/- 28.8 mg/kg/day. Compared to pre- and post-
AmBisome
therapy there was a significantly increased cyclosporin concentration in blood during
AmBisome
therapy. Side-effects with possible association to
AmBisome
therapy included low serum potassium (36%), increase in serum creatinine (31%), rise in alkaline phosphatases (26%) and fever (3%). The overall mean increase in serum creatinine was 20%. Other possible side-effects like headache, abdominal pain, rash, rise in bilirubin, cramps and pancreatitis was seen in single patients.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. 770 25